All In Biotech

Drug Trial Radar · NCT04453436

HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil

HIV Drug Resistance Profiles Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Sep 1, 2023

Primary completion

Dec 31, 2024

Study completion Oct 31, 2026

Sponsor

Lead sponsor
Federal University of São PauloAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Gilead Sciences
First posted
Jul 1, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Brazil was the first middle-income country to provide free and universal access to antiretroviral drugs to HIV infected individuals. Since 2014 local guidelines recommend that all HIV infected individuals be started on therapy regardless of CD4 count. Since January 2017, all patients are started on a DTG containing triple regimen. As of November 2018, 170,000 individuals were receiving DTG through the public health system. It is a public health priority to evaluate the risk of virologic failure and the subsequent development of INSTI resistance in these real-life settings. Our preliminary data from Brazil indicated a high virologic failure rate of 8% after 18 months of treatment TL+D. Our central hypothesis is that TDR may be associated and contribute to virologic failure with DTG in clinical practice. To test this central hypothesis, we will identify PLWH failing DTG containing regimens in Brazil. The insights generated with these studies will contribute to a more effective use of second generation INSTI in the future.

Conditions

  • HIV
  • Drug
  • Resistance

Interventions

  • Tenofovir DisoproxilDrug

    Genotipic resistance test

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HIV RNA Viral LoadTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laboratório de Retrovirologia, EP2

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.